Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Immunocore Holdings (IMCR) EBIT Margin: 2021-2025

Historic EBIT Margin for Immunocore Holdings (IMCR) over the last 3 years, with Sep 2025 value amounting to -6.92%.

  • Immunocore Holdings' EBIT Margin rose 368.00% to -6.92% in Q3 2025 from the same period last year, while for Sep 2025 it was -11.88%, marking a year-over-year increase of 1108.00%. This contributed to the annual value of -22.71% for FY2024, which is 120.00% up from last year.
  • Per Immunocore Holdings' latest filing, its EBIT Margin stood at -6.92% for Q3 2025, which was up 54.46% from -15.18% recorded in Q2 2025.
  • In the past 5 years, Immunocore Holdings' EBIT Margin registered a high of 0.20% during Q4 2021, and its lowest value of -37.57% during Q1 2024.
  • In the last 3 years, Immunocore Holdings' EBIT Margin had a median value of -21.81% in 2023 and averaged -19.50%.
  • As far as peak fluctuations go, Immunocore Holdings' EBIT Margin tumbled by 1,069bps in 2024, and later soared by 3,372bps in 2025.
  • Immunocore Holdings' EBIT Margin (Quarterly) stood at 0.20% in 2021, then reached -24.30% in 2023, then soared by 116bps to -23.14% in 2024, then spiked by 368bps to -6.92% in 2025.
  • Its EBIT Margin stands at -6.92% for Q3 2025, versus -15.18% for Q2 2025 and -3.85% for Q1 2025.